Valuation: Bolt Biotherapeutics, Inc.

Market Cap 6.9M 6.05M 5.71M 5.21M 9.75M 661M 9.82M 68.37M 26.44M 337M 25.89M 25.33M 1.08B P/E 2026 *
-0.15x
P/E 2027 * -0.18x
Enterprise Value 6.9M 6.05M 5.71M 5.21M 9.75M 661M 9.82M 68.37M 26.44M 337M 25.89M 25.33M 1.08B EV / Sales 2026 *
34.5x
EV / Sales 2027 * 1.97x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-0.28%
1 week+0.56%
Current month-10.05%
1 month-7.01%
3 months-14.76%
6 months-20.44%
Current year-34.53%
1 week 3.38
Extreme 3.38
3.9
1 month 3.1
Extreme 3.1
4.36
Current year 3.1
Extreme 3.1
7.2
1 year 3.1
Extreme 3.1
7.2
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
283.6
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 55 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 55 2024-05-14
Chairman 56 2024-09-03
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Sell

Chief Operating Officer

-6,850 0.3556%
9/18/26 Sell

Controller/Auditor

-4,077 0.2116%
9/18/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%+0.56%-35.27%-82.62% 6.9M
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.47%+0.45%+28.80%+143.80% 27.52B
Weighted average by Cap. -0.77%+0.31%+36.31%+129.11%

Financials

2026 *2027 *
Net sales 200K 176K 166K 151K 283K 19.16M 285K 1.98M 767K 9.78M 751K 735K 31.44M 3.5M 3.07M 2.9M 2.64M 4.95M 335M 4.98M 34.7M 13.42M 171M 13.14M 12.86M 550M
Net income -47.4M -41.62M -39.26M -35.78M -67.03M -4.54B -67.49M -470M -182M -2.32B -178M -174M -7.45B -47.5M -41.7M -39.34M -35.85M -67.17M -4.55B -67.63M -471M -182M -2.32B -178M -174M -7.47B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-09-25 US$3.580 -0.28% 4,101
26-09-24 US$3.590 -1.64% 15,280
26-09-23 US$3.650 -1.62% 5,105
26-09-22 US$3.710 +3.34% 17,854
26-09-21 US$3.590 +0.84% 22,454
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.580USD
Average target price
29.00USD
Spread / Average Target
+710.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock